Symphogen A/S
- Country
- π©π°Denmark
- Ownership
- Subsidiary
- Established
- 2000-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.symphogen.com
Clinical Trials
33
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (29 trials with phase data)β’ Click on a phase to view related trials
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 48
- Registration Number
- NCT04672434
- Locations
- πΊπΈ
START Midwest, Grand Rapids, Michigan, United States
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
πΊπΈNEXT Oncology, San Antonio, Texas, United States
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
- Conditions
- Metastatic CancerSolid Tumor
- Interventions
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 78
- Registration Number
- NCT04641871
- Locations
- πΊπΈ
University of Colorado, Aurora, Colorado, United States
πΊπΈMayo Clinic - Jacksonville, Jacksonville, Florida, United States
πΊπΈMoffitt Cancer Center, Tampa, Florida, United States
Sym004 Versus TAS-102 in Patients With mCRC
- Conditions
- Metastatic Colorectal CancerColorectal Cancer MetastaticCarcinoma
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Symphogen A/S
- Registration Number
- NCT03717038
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
- Conditions
- Colorectal Cancer MetastaticMetastatic Colorectal CancerCarcinoma
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 2
- Registration Number
- NCT03549338
- Locations
- πΊπΈ
City of Hope - Comprehensive Cancer Center, Duarte, California, United States
πΊπΈEmory University Hospital, Atlanta, Georgia, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 24
- Registration Number
- NCT03489343
- Locations
- πΊπΈ
South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
πΊπΈThe University of Texas MD Anderson Cancer Center, Houston, Texas, United States
πΊπΈNEXT Oncology, San Antonio, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
LAG-3 Inhibitors Show Promise in Cancer Immunotherapy, Market Expected to Surge
β’ The LAG-3 inhibitors market is poised for substantial growth, projected to exceed USD 3 billion by 2029, driven by increasing adoption in cancer therapy. β’ Opdualag, the first approved LAG-3 therapy, has demonstrated significant commercial success, generating substantial revenue and paving the way for further drug development. β’ Clinical trials are actively evaluating LAG-3 inhibitors in combination with other therapies, showing potential across various cancers, autoimmune disorders, and inflammatory diseases. β’ Several LAG-3 inhibitor candidates are in late-stage clinical trials, indicating a robust pipeline and growing interest from major pharmaceutical companies.